Chimeric antigen receptor (CAR) T-cell therapy, described as a "living drug," is now available for patients with relapsed/refractory multiple myeloma who have been treated with four or more prior lines of therapy.
The US Food and Drug Administration (FDA) said these patients represent an "unmet medical need" when it granted approval for the new product idecabtagene vicleucel (ide-cel; Abecma), developed by bluebird bio and Bristol-Myers Squibb.
Ide-cel is the first CART-cell therapy to gain approval for use in multiple myeloma. It is also the first CAR T-cell therapy to target B-cell maturation antigen.
Previously approved CAR T-cell products target CD19 and have been approved for use in certain types of leukemia and lymphoma.
All the CAR T-cell therapies are customized treatments that are created specifically for each individual patient from their own blood. The patient's own T cells are removed from the blood, are genetically modified and expanded, and are then infused back into the patient. These modified T cells then seek out and destroy blood cancer cells, and they continue to do so long term.
In some patients, this has led to eradication of disease that had previously progressed with every other treatment that had been tried results that have been described as "absolutely remarkable" and "one-shot therapy that looks to be curative."
However, this cell therapy comes with serious adverse effects, including neurologic toxicity and cytokine release syndrome (CRS), which can be life threatening. For this reason, all these products have a risk evaluation and mitigation strategy, and the use of CAR T-cell therapies is limited to designated centers.
In addition, these CAR T-cells products are phenomenally expensive; hospitals have reported heavy financial losses with their use, and patients have turned to crowdfunding to pay for these therapies.
The FDA noted that approval of ide-cel for multiple myeloma is based on data from a multicenter study that involved 127 patients with relapsed/refractory disease who had received at least three prior lines of treatment.
The results from this trial were published in February 2021 in the New England Journal of Medicine (NEJM).
An expert not involved in the trial described the results as "phenomenal."
Krina Patel, MD, an associate professor in the Department of Lymphoma/Myeloma at the University of Texas MD Anderson Cancer Center, Houston, Texas, said that "the response rate of 73% in a patient population with a median of sixlines of therapy, and with one-third of those patients achieving a deep response of complete response or better, is phenomenal.
"We are very excited as a myeloma community for this study of idecabtagene vicleucel for relapsed/refractory patients," Patel told Medscape Medical News at the time.
The lead investigator of the study, Nikhil Munshi, MD, of Dana-Farber Cancer Institute, Boston, Massachusetts, commented: "The results of this trial represent a true turning point in the treatment of this disease. In my 30 years of treating myeloma, I have not seen any other therapy as effective in this group of patients."
In my 30 years of treating myeloma, I have not seen any other therapy as effective in this group of patients. Dr Nikhil Munshi
Both experts highlighted the poor prognosis for patients with relapsed/refractory disease. Recent decades have seen a flurry of new agents for myeloma, and there are now three main classes of agents: immunomodulatory agents, proteasome inhibitors, and anti-CD38 antibodies.
Nevertheless, in some patients, the disease continues to progress. For patients for whom treatments with all three classes of drugs have failed, the median progression-free survival is 3 to 4 months, and the median overall survival is 9 months.
In contrast, the results reported in the NEJM article showed that overall median progression-free survival was 8.8 months, but it was more than double that (20.2 months) for patients who achieved a complete or stringent complete response.
Estimated median overall survival was 19.4 months, and the overall survival was 78% at 12 months. The authors notethat overall survival data are not yet mature.
The patients who were enrolled in the CAR T-cell trial had undergone many previous treatments. They had undergone a median for six prior drug therapies (range, three to 16), and most of the patients (120, 94%) had also undergone autologous hematopoietic stem cell transplant.
In addition, the majority of patients (84%) had disease that was triple refractory (to an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody), 60% had disease that was penta-exposed (to bortezomib, carfilzomib, lenalidomide, pomalidomide, and daratumumab), and 26% had disease that was penta-refractory.
In the NEJM article, the authors report that about a third of patients had a complete response to CAR T-cell therapy.
At a median follow-up of 13.3 months, 94 of 128 patients (73%) showed a response to therapy (P < .001); 42 (33%) showed a complete or stringent complete response;and 67 patients (52%) showed a "very good partial response or better," they write.
In the FDA announcement of the product approval, the figures for complete response was slightly lower. "Of those studied, 28% of patients showed complete response or disappearance of all signs of multiple myeloma to Abecma, and 65% of this group remained in complete response to the treatment for at least 12 months," the agency noted.
The FDA also noted that treatment with Abecma can cause severe side effects. The label carries a boxed warning regarding CRS, hemophagocytic lymphohistiocytosis/macrophage activation syndrome, neurologic toxicity, and prolonged cytopenia, all of which can be fatal or life threatening.
The most common side effects of Abecma are CRS, infections, fatigue, musculoskeletal pain, and a weakened immune system. Side effects from treatment usually appear within the first 1 to 2 weeks after treatment, but some side effects may occur later.
The agency also noted that, to further evaluate the long-term safety of the drug, it is requiring the manufacturer to conduct a postmarketing observational study.
"The FDA remains committed to advancing novel treatment options for areas of unmet patient need," said Peter Marks, MD, PhD, director of the FDA's Center for Biologics Evaluation and Research.
"While there is no cure for multiple myeloma, the long-term outlook can vary based on the individual's age and the stage of the condition at the time of diagnosis. Today's approval provides a new treatment option for patients who have this uncommon type of cancer."
For more from Medscape Oncology, join us on Twitter and Facebook.
- FDA Responds to Creative Medical Technology Holdings Regarding Its ImmCelz IND for Stroke Treatment - KPVI News 6 - May 14th, 2021
- Duluth health center specializes in regenerative medicine, hormone replacement therapy - Duluth News Tribune - May 14th, 2021
- Dr. Krger on Toxicities Associated With Allogeneic Stem Cell Transplant in Myeloma - OncLive - May 14th, 2021
- Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its... - May 14th, 2021
- Genenta Phase I/II Glioblastoma Data at ASGCT Show Temferon Delivered Tumor-Focused Interferon ExpressionData presented at the 2021 American Society... - May 14th, 2021
- ViaCyte To Participate In World Medical Innovation Forum Panel On Future Of Cell Therapy For Type 1 Diabetes - PRNewswire - May 14th, 2021
- Omeros' Narsoplimab Pivotal Trial Data to Be Shared as an Oral Presentation at the European Hematology Association Congress - Business Wire - May 14th, 2021
- Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in May - Business Wire - May 14th, 2021
- Outlook for multiple myeloma: Figures and factors that affect it - Medical News Today - May 14th, 2021
- Global Regenerative Medicine for Cartilage Market Report 2021: Companies are Continuously Focusing on Introducing New Technologies to Survive in the... - May 14th, 2021
- UB celebrates 175th anniversary of its origins in study of medicine - UB Now: News and views for UB faculty and staff - University at Buffalo Reporter - May 14th, 2021
- Stem cell therapy for COVID-19 and ARDS - News-Medical.Net - May 7th, 2021
- Experimental COVID-19 lung treatment being tested at Ontario hospitals - CityNews Toronto - May 7th, 2021
- EP. 4: Optimizing Patient Selection for CAR T-Cell Therapy - OncLive - May 7th, 2021
- Could stem cells improve the outcome of ARDS in severe COVID-19? - News-Medical.Net - May 7th, 2021
- Motixafortide Reaches Primary End Point of Improved Stem Cell Mobilization in Multiple Myeloma Trial - Cancer Network - May 7th, 2021
- Restricting the Growth and Spread of Head and Neck Cancers - Technology Networks - May 7th, 2021
- The global stem cell therapy market is projected to reach USD 401 million by 2026 from - GlobeNewswire - May 7th, 2021
- UCLA team discovers how to restrict growth, spread of head and neck cancers | UCLA - UCLA Newsroom - May 7th, 2021
- NUS scientists found a key element that affects how genes are expressed in blood stem cells - Newswise - May 7th, 2021
- Citius Pharmaceuticals to Present Mino-Lok and COVID-related Respiratory Treatment Update at Benzinga Global Small Cap Conference on Thursday, May 13... - May 7th, 2021
- Mesoblast says its stem cell treatment saved lives of severely ill COVID patients - Stockhead - May 2nd, 2021
- Antiviral T cells safe, effective as off-the-shelf therapy for painful complication after stem cell transplants - News-Medical.Net - May 2nd, 2021
- Antiviral T cells protected, viable as off-the-shelf treatment for painful complication stem cells - Microbioz India - May 2nd, 2021
- Desperate family of boy, 9, with leukaemia have 10 days to save his life... - The Sun - May 2nd, 2021
- Orchard Therapeutics Announces Multiple Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy - GlobeNewswire - May 2nd, 2021
- Investigating CAR T-Cell Therapy for Use in Different Disease Types - Targeted Oncology - May 2nd, 2021
- Enhanced inhibition of tumor growth using TRAIL-overexpressing adipose-derived stem cells in combination with the chemotherapeutic agent CPT-11 in... - May 2nd, 2021
- Thomas Smeenk on Hemostemix's autologous stem cell therapy technology and why some call it 'the fountain of youth' - InvestorIntel - April 28th, 2021
- Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer... - April 28th, 2021
- Fate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meeting - GlobeNewswire - April 28th, 2021
- Therapeutic Solutions International Reports Regression of Established Tumors by Combining its Cancer Blood Vessel Targeting Immunotherapy with Low... - April 28th, 2021
- A review of baculovirus vectors in gene therapy | BTT - Dove Medical Press - April 28th, 2021
- Stem Cell Therapy for COPD: Hope and Exploitation - DocWire News - April 26th, 2021
- Axion BioSystems Announces Formation of Scientific Advisory Board - Business Wire - April 26th, 2021
- Global Cell Therapy Market By Therapy Type, By Therapeutic Area, By End User, By Cell Type, By Regional Outlook, Industry Analysis Report and... - April 24th, 2021
- Pure Red Cell Aplasia following ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation: Resolution with Daratumumab Treatment - DocWire... - April 24th, 2021
- Advancing the Development of Safe and Effective Regenerative Medicine Products | FDA - FDA.gov - April 24th, 2021
- New method helps map the specialized diversity and spatial location of cells within a tissue or tumor - News-Medical.Net - April 24th, 2021
- Chimeric embryo may have medical implications The Campus - The Campus - April 24th, 2021
- Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France - a cohort study using the French National... - April 24th, 2021
- Guenther Koehne, MD, Highlights Recent Advancements in the Treatment of Blood Cancers - Oncology Learning Network - April 24th, 2021
- Rinri Therapeutics raises 10 million to advance stem cell therapy for hearing loss - The Star - April 24th, 2021
- Cancer Diagnosis in Patient Given LentiGlobin Revised to Severe Anemia - Sickle Cell Anemia News - April 24th, 2021
- Hodgkin lymphoma: Symptoms, outlook, treatment, and more - Medical News Today - April 24th, 2021
- Tissue Repair, Mitochondrial Function and Wound Healing Explored in 2021 APS Presidents Symposium - Newswise - April 24th, 2021
- Axion BioSystems Announces Formation of Scientific Advisory Board - BioSpace - April 20th, 2021
- Avalon GloboCare is seeking to tap the power of cells to fight cancer and coronavirus - Proactive Investors USA - April 20th, 2021
- Rinri Therapeutics Raises 10 million from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Therapy to Restore Hearing Loss -... - April 20th, 2021
- Global Regenerative Medicines Market 2020-2030: Opportunities in Drug Approvals and Strong Pipeline of Cell and Gene Therapies & Multiple... - April 20th, 2021
- FDA Grants Orphan Drug Status to Novel IRAK4 Inhibitor in AML and MDS - Targeted Oncology - April 20th, 2021
- Vertex Drops $900 Million to Expand Partnership with CRISPR Therapeutics - BioSpace - April 20th, 2021
- Kaleido Biosciences Announces Collaboration with Robert Jenq, MD, to Explore Potential of its Microbiome Metabolic Therapies (MMT) in Preventing... - April 20th, 2021
- Partner Content | Being bionic: the future of regenerative medicine - TheSpec.com - April 14th, 2021
- Ohio State Recruits Top Oncologist to Expand Cell Therapy Program, Lead Bone Marrow Transplant Services - Wexner Medical Center - The Ohio State... - April 14th, 2021
- Leukemia Cutis: Symptoms and Treatment - Healthline - April 14th, 2021
- Green: Variants and outbreaks continue to put stress on hospitals - Vermont Biz - April 14th, 2021
- CRISPR Therapies Pipeline Insights 2021: Analysis of Key Companies, Emerging Therapies, Recent Happenings and Futuristic Trends - GlobeNewswire - April 14th, 2021
- Consortium to investigate role of neurofilament light chain in neurodegenerative diseases Washington University School of Medicine in St. Louis -... - April 14th, 2021
- Man's heart healed by stem cell therapy and love of an old flame - Leeds Live - April 12th, 2021
- New pediatric cancer treatment method being used in Iran - Tehran Times - April 12th, 2021
- Personalized Cancer Vaccine Shows Early Efficacy in Patients With Diverse Tumor Types - Technology Networks - April 12th, 2021
- 1000th Stem Cell Transplant Given to Girl Who Is One in a Million - Stanford Children's Health Blog - Stanford Children's Health - April 10th, 2021
- Home : Stem Cell Treatments - April 10th, 2021
- Researchers discover unique regenerative property of cells in the early human embryo - News-Medical.net - April 10th, 2021
- Study reveals sex-differences in aging of the brain stem cell niche - News-Medical.net - April 10th, 2021
- Antibiotics need further study in cancer treatments - Chicago Daily Herald - April 10th, 2021
- Prolonged infection and inflammation drain immune responses as we age - Baylor College of Medicine News - April 10th, 2021
- Toward a transformative therapy for sickle cell patients - News-Medical.Net - April 10th, 2021
- Mass. Residents 55+ Or With 1 Medical Condition Can Now Get COVID Vaccine | WBZ NewsRadio 1030 - iHeartRadio - April 6th, 2021
- Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population - DocWire News - April 6th, 2021
- BioRestorative Therapies Announces Appointment of Nickolay V. Kukekov, Ph.D to its Board of Directors - BioSpace - April 6th, 2021
- LGL Leukemia: Overview, Symptoms, and Treatment - Healthline - April 3rd, 2021
- Novel T-Cell Therapy MT-401 Under Evaluation in Post-Transplant AML - OncLive - April 3rd, 2021
- Funding the Next Generation of Cancer Therapies - Genetic Engineering & Biotechnology News - April 3rd, 2021
- Do Therapies for Alzheimer's & Parkinson's that Clear Abnormal Brain Proteins Make the Diseases Worse? - BioSpace - April 3rd, 2021
- Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy - DocWire News - April 1st, 2021
- Insulin 100: How the road to a diabetes cure is yielding better treatments - News@UofT - April 1st, 2021
- The Government's Watchful Eye on Fraud Stemming from Stem Cell Therapy - Lexology - April 1st, 2021
- Introducing a neuro regenerative gene into mice with spinal cord injury improves motor function - News-Medical.net - April 1st, 2021